A phenotypic combination of idiopathic VF and Brugada syndrome.
This case study shows a young male presenting a mixture of two disease entities: (1) Brugada syndrome with a nearly-normal baseline electrocardiogram and positive Ajmaline drug challenge as well as (2) idiopathic ventricular fibrillation including extremely short-coupled monomorphic ventricular premature beats (VPB) triggering ventricular fibrillation (coupling interval 318 ± 21 ms). In this phenotypic patient group-more suggestive of idiopathic ventricular fibrillation due to the ultra-short coupling interval of the VPBs-drug treatment with a class IA agent such as Quinidine might be an important option to implantable cardioverter-defibrillator and ablation therapy.
Department of Cardiology, Elisabethinen University Teaching Hospital for the Universities of Innsbruck and Graz, Linz, Austria. martin.martinek@elisabethinen.or.at
Martin
M
Martinek
Helmut
H
Purerfellner
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000404:Ajmaline; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy; D053840:Brugada Syndrome / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy; D002037:Bundle-Branch Block / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery; D017115:Catheter Ablation; D017147:Defibrillators, Implantable; D004562:Electrocardiography; D006801:Humans; D008297:Male; D019919:Prosthesis Implantation; D011802:Quinidine / Q000627:therapeutic use; D016896:Treatment Outcome; D014693:Ventricular Fibrillation / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy; D018879:Ventricular Premature Complexes / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000404:Ajmaline; D011802:Quinidine